Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NGM Biopharmaceuticals stock | 20.63

Own NGM Biopharmaceuticals stock in just a few minutes.


Fact checked

NGM Biopharmaceuticals, Inc is a biotechnology business based in the US. NGM Biopharmaceuticals shares (NGM) are listed on the NASDAQ and all prices are listed in US Dollars. NGM Biopharmaceuticals employs 186 staff and has a trailing 12-month revenue of around USD$98.7 million.

How to buy shares in NGM Biopharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for NGM Biopharmaceuticals. Find the stock by name or ticker symbol: NGM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until NGM Biopharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$20.63, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of NGM Biopharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of NGM Biopharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted NGM Biopharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, NGM Biopharmaceuticals's share price has had significant positive movement.

Its last market close was USD$20.63, which is 21.52% up on its pre-crash value of USD$16.19 and 123.15% up on the lowest point reached during the March crash when the shares fell as low as USD$9.245.

If you had bought USD$1,000 worth of NGM Biopharmaceuticals shares at the start of February 2020, those shares would have been worth USD$693.37 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,214.28.

NGM Biopharmaceuticals share price

Use our graph to track the performance of NGM stocks over time.

NGM Biopharmaceuticals shares at a glance

Information last updated 2020-11-26.
Latest market close USD$20.63
52-week range USD$9.245 - USD$24.54
50-day moving average USD$18.8536
200-day moving average USD$19.1158
Wall St. target price USD$30.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.457

Buy NGM Biopharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NGM Biopharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NGM Biopharmaceuticals price performance over time

Historical closes compared with the close of $20.63 from 2020-11-16

1 week (2020-11-20) -11.80%
1 month (2020-10-30) 18.97%
3 months (2020-08-28) 14.23%
6 months (2020-05-28) 1.13%
1 year (2019-11-27) 26.02%
2 years (2018-11-26) N/A
3 years (2017-11-26) N/A
5 years (2015-11-26) N/A

NGM Biopharmaceuticals financials

Revenue TTM USD$98.7 million
Gross profit TTM USD$41.3 million
Return on assets TTM -16.3%
Return on equity TTM -29.37%
Profit margin -91.64%
Book value $4.015
Market capitalisation USD$1.6 billion

TTM: trailing 12 months

Shorting NGM Biopharmaceuticals shares

There are currently 4.0 million NGM Biopharmaceuticals shares held short by investors – that's known as NGM Biopharmaceuticals's "short interest". This figure is 1.5% down from 4.0 million last month.

There are a few different ways that this level of interest in shorting NGM Biopharmaceuticals shares can be evaluated.

NGM Biopharmaceuticals's "short interest ratio" (SIR)

NGM Biopharmaceuticals's "short interest ratio" (SIR) is the quantity of NGM Biopharmaceuticals shares currently shorted divided by the average quantity of NGM Biopharmaceuticals shares traded daily (recently around 135114.98305085). NGM Biopharmaceuticals's SIR currently stands at 29.5. In other words for every 100,000 NGM Biopharmaceuticals shares traded daily on the market, roughly 29500 shares are currently held short.

However NGM Biopharmaceuticals's short interest can also be evaluated against the total number of NGM Biopharmaceuticals shares, or, against the total number of tradable NGM Biopharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NGM Biopharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 NGM Biopharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.1592% of the tradable shares (for every 100,000 tradable NGM Biopharmaceuticals shares, roughly 159 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against NGM Biopharmaceuticals.

Find out more about how you can short NGM Biopharmaceuticals stock.

NGM Biopharmaceuticals share dividends

We're not expecting NGM Biopharmaceuticals to pay a dividend over the next 12 months.

NGM Biopharmaceuticals overview

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site